
European Commission approves Tevimbra for small cell lung cancer
The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). The new indication is based on results of RATIONALE-312 study, which demonstrated statistically significant overall survival benefit for patients treated with Tevimbra… Read More












